Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Holding 0.35.
View:
Post by Beano349 on Nov 01, 2024 3:45pm

Holding 0.35.

Are warrants expiring in November? And at what price? I don't know where to find this information.
Comment by Beano349 on Nov 01, 2024 3:45pm
0.25, my by on the typo
Comment by 2b7f6fab on Nov 01, 2024 3:57pm
I don't see any expiring soon.  Footnote 9 to the financials shows the warrants and when they expire.  In June 30, 2023 and September 7, 2023 there were $0.35 two year warrants issued.  And November 29, 2023 $0.28 five year warrants issued.
Comment by Pandora on Nov 01, 2024 7:17pm
TORONTO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to destroy various cancers, bacteria and viruses, safely and effectively, is ...more  
Comment by 2b7f6fab on Nov 01, 2024 7:37pm
Yes I do see those warrants on the schedule from the 1st Q, 2024 footnotes.  Just over a million warrants @ 35 cents.  I suspect they will be extended for 3 more years.  Below is the schedule, not sure how it will format correctly or not when this posts.  Highlighted in blue with 0.63 at the end indicating the remaining life from 3/31/2024 which is 7.5 months from 3/31/2024 ...more  
Comment by riverrrow on Nov 02, 2024 3:06am
They seem to announce the extension of warrants at the last minute.  I'm guessing Friday November 15 for these.  GLTA.
Comment by Oilminerdeluxe on Nov 02, 2024 6:30am
The next couple of updates will no doubt be watched with interested eyes. Hopefully, they will update us on stuff soon again. 
Comment by menoalittle on Nov 02, 2024 11:51am
I suspect they'll want to close this PP before releasing any BTD related news.  But... given how many eyes are undoubtedly on this right now and anxiously waiting for that... perhaps news of any sort risks unwittingly lighting the fuse to the powderkeg this is sitting on. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250